Gelion, the battery technology developer focused on sulfur-based cathode materials, has set out a goal of earning commercial Revenue from partner agreements in its 2027 financial year. In final results for the year ended 30 June 2026, published on 22 October 2026, the company reported total income of £2.5m and an adjusted EBITDA loss of £4.4m, with both figures coming in better than market consensus according to a summary of the results.
What the company does
Gelion is developing next-generation battery materials built around its nano-encapsulated sulfur cathode technology, which it aims to commercialise for lithium-ion and sodium-ion batteries. Its target markets include defence, aerospace, drones, consumer devices and electric vehicles. The company works with industrial partners through joint development agreements rather than Manufacturing batteries at scale itself.
Latest developments
The results highlighted strategic collaborations with TDK and Nissan, expansion into the US market and further validation of the technology for defence applications. After the period end, Gelion signed a funded development and scale-up agreement worth £2.0m with Mitsui Kinzoku, the Japanese materials group, which the chief executive said would help develop and scale up the sulfur battery technology.
Management said its priorities were delivering milestones under existing collaborations, validating the technology with partners and scaling up production. Plans include increasing laboratory-scale output of cathode active material, advancing pilot-scale production and demonstrating a solid-state electric vehicle application. The company also published a patents update in September 2026 and a directorate change earlier in the year.
Financial and Dividend picture
Total income of £2.5m compared with £2.7m a year earlier, against consensus of about £2.1m. Grant income and Research and Development tax incentives rose to £2.4m from £1.8m, while product revenue fell to nil from £0.9m. The adjusted EBITDA loss widened slightly to £4.4m from £4.1m, but was narrower than the £4.9m loss forecast by analysts. The adjusted loss before tax was £5.3m.
Research and development spending rose to £3.8m, and overheads increased to £3.0m from £2.5m, reflecting US expansion and Business development. Reported cash was £7.6m at 30 June 2026, and pro forma cash including grants and tax receivables was £9.6m, up from £4.1m a year earlier, following a net Capital raise of £9.9m in 2025. The company has no Debt and does not pay a dividend.
Sector and index context
Gelion sits in the technology and clean energy part of the FTSE AIM All Share Index, alongside other pre-revenue developers seeking to turn laboratory results into commercial contracts. Interest in alternatives to conventional lithium-ion chemistries has grown because of concerns over the cost and Supply of materials such as nickel and cobalt, but the path from research to mass production is typically long and capital intensive.
Key risks
The company is still loss-making and relies heavily on grants, tax incentives and partner funding. Its commercial timetable depends on partners choosing to move from development to supply agreements, which is outside its direct control, and the absence of product revenue in the latest year underlines how early the business remains. Further fundraising may be needed if milestones slip, and larger battery companies are pursuing competing technologies.
What to watch next
Investors will look for milestone payments under the TDK, Nissan and Mitsui Kinzoku arrangements, any new partnerships in drones or electric vehicles, progress on pilot-scale production and evidence that the targeted commercial revenue in the 2027 financial year is on track.






Please wait processing your request...